Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (646)	3/6/2002 9:22:53 AM
From: tuck	Respond to of 1005

>>CHAPEL HILL, N.C., March 6 /PRNewswire-FirstCall/ -- POZEN Inc. (Nasdaq: POZN - news), a pharmaceutical development company with a portfolio of candidates for the treatment of migraine, announced today that it has submitted the final results of its six-month mouse carcinogencity study for its lead product candidate, MT 100, to the Food and Drug Administration (FDA). The final results confirmed preliminary findings that indicated that MT 100 was not carcinogenic in the test species, p53 transgenic mice. The preliminary results were submitted to the FDA in February. MT 100 is being developed as an oral, first-line treatment for migraine pain and associated symptoms. The effectiveness of the product candidate has been demonstrated in numerous Phase II and Phase III clinical studies involving thousands of patients. Last year the company announced that MT 100 provided comparable efficacy with fewer incidences of side effects when tested against Imitrex®, the worldwide market leader.<< snip Cheers, Tuck